[go: up one dir, main page]

DE69528624D1 - Anti-Fas Antikörper gegen rheumatische Krankheiten - Google Patents

Anti-Fas Antikörper gegen rheumatische Krankheiten

Info

Publication number
DE69528624D1
DE69528624D1 DE69528624T DE69528624T DE69528624D1 DE 69528624 D1 DE69528624 D1 DE 69528624D1 DE 69528624 T DE69528624 T DE 69528624T DE 69528624 T DE69528624 T DE 69528624T DE 69528624 D1 DE69528624 D1 DE 69528624D1
Authority
DE
Germany
Prior art keywords
fas
monoclonal antibody
antibodies against
rheumatic diseases
fas antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528624T
Other languages
English (en)
Other versions
DE69528624T2 (de
Inventor
Kusiki Nishioka
Shin Yoneyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69528624D1 publication Critical patent/DE69528624D1/de
Publication of DE69528624T2 publication Critical patent/DE69528624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69528624T 1994-09-27 1995-09-27 Anti-Fas Antikörper gegen rheumatische Krankheiten Expired - Lifetime DE69528624T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (2)

Publication Number Publication Date
DE69528624D1 true DE69528624D1 (de) 2002-11-28
DE69528624T2 DE69528624T2 (de) 2003-06-26

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528624T Expired - Lifetime DE69528624T2 (de) 1994-09-27 1995-09-27 Anti-Fas Antikörper gegen rheumatische Krankheiten

Country Status (9)

Country Link
US (1) US6086877A (de)
EP (1) EP0709097B1 (de)
KR (1) KR100371000B1 (de)
AT (1) ATE226447T1 (de)
CA (1) CA2158822C (de)
DE (1) DE69528624T2 (de)
DK (1) DK0709097T3 (de)
ES (1) ES2182860T3 (de)
PT (1) PT709097E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
ZA982371B (en) * 1997-03-21 1998-09-28 Sankyo Co Humanized anti-human fas antibody
PT1087993E (pt) 1998-06-18 2008-07-04 Imed Ab Péptidos fas e anticorpos para modular a apoptose
HUP0201333A3 (en) 1999-05-24 2004-11-29 Sankyo Company Ltd Chuo Ku Medicinal compositions containing anti-fas antibody
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
WO2002034912A1 (fr) 2000-10-24 2002-05-02 New Ind Res Organization Genomes participant a l'arthrite rhumatoide, procede de diagnostic de celle-ci, procede d'evaluation de la possibilite d'apparition de celle-ci, kit de diagnostic et methode et remedes therapeutiques destines a l'ar
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
JP4560822B2 (ja) * 2008-08-01 2010-10-13 Ａｘｉｓ株式会社 変形性関節症治療剤又は予防剤
JP5792636B2 (ja) * 2010-01-29 2015-10-14 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
KR20120115383A (ko) * 2010-01-29 2012-10-17 가부시키가이샤 아크시스 변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
BR112014017229B1 (pt) 2012-01-12 2022-05-17 Auxilium International Holdings, Inc Ácido nucleico recombinante, cassette de expressão, vetor, célula hospedeira recombinante, método de produção da colagenase i ou ii, colagenase i ou ii, composição farmacêutica, e método de produção de um produto de droga
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
JP7558654B2 (ja) 2017-03-01 2024-10-01 エンド ベンチャーズ アンリミテッド カンパニー セルライトを評価及び処置するための装置及び方法
BR112019020394A2 (pt) 2017-03-28 2020-04-22 Endo Ventures Ltd método melhorado de produção de colagenase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
DE69233441T2 (de) * 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
EP0603194A4 (de) * 1991-07-05 1994-12-07 Seragen Inc Zum rezeptor des epidermalen wachstumsfaktors zielgesteuerte moleküle zur behandlung entzündlicher arthritis.
AU666577B2 (en) * 1992-08-19 1996-02-15 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
KR960704938A (ko) * 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
DE69528624T2 (de) 2003-06-26
KR100371000B1 (ko) 2003-07-12
CA2158822C (en) 2008-12-23
EP0709097A1 (de) 1996-05-01
ES2182860T3 (es) 2003-03-16
US6086877A (en) 2000-07-11
EP0709097B1 (de) 2002-10-23
KR960010024A (ko) 1996-04-20
DK0709097T3 (da) 2003-02-24
PT709097E (pt) 2003-03-31
ATE226447T1 (de) 2002-11-15
CA2158822A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
ATE226447T1 (de) Anti-fas antikörper gegen rheumatische krankheiten
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
CA2310888A1 (en) Monoclonal human natural antibodies
TR200101205T1 (tr) ímmn hastalìklarìn tedavisi i‡in bir farmas”tik terkip
DE60143535D1 (de) Humane antikörper gegen cd40
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
DE59608213D1 (de) Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
WO2003054018A3 (en) Anti-tirc7 antibodies in therapy of inflammatory diseases
Patterson-Fortin et al. Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
Kanwar et al. Anti‐desmoglein antibody‐negative paraneoplastic pemphigus successfully treated with rituximab
WO2005058358A3 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition